Clear Value Plus and Value Pathways powered by NCCN - Frequently Asked Questions

Earlier this year, the National Comprehensive Cancer Network (NCCN), The US Oncology Network and McKesson Specialty Health announced the availability of Clear Value Plus, a first-of-its-kind clinical quality and regimen support system which incorporates Value Pathways powered by NCCN. Value Pathways powered by NCCN establishes a new standard for quality oncology care, backed by transparent development processes and recognized by NCCN – the leader in evidence-based content. The combined solution provides:

- A common technology platform for measuring quality and value in cancer care
- An opportunity to gain greater insight into the use of evidence- and value-based medicine and how it is incorporated into practices’ workflow
- Evidence-based treatment options, including peer reviewed indications of efficacy, toxicity and cost, available to providers at the point of care

In response to inquiries received from pharmaceutical and biotech organizations, we have developed this document of frequently asked questions to clarify aspects of Clear Value Plus and Value Pathways powered by NCCN.

Value Pathways powered by NCCN

Q. How are Value Pathways different from Level I Pathways?
- Value Pathways are the next evolution of Level I Pathways. Value Pathways are built upon the NCCN Guidelines, ensuring concordance with the gold standard for evidence-based medicine in oncology. Value Pathways leverage the pathway development process pioneered by physicians in The US Oncology Network for Level I Pathways. This collaboration ensures that the industry-leading Level I Pathways will continue to evolve to further support providers in the delivery of high-quality, cost-effective patient care.

Q. Will Value Pathways replace Level I Pathways?
- Yes, Value Pathways are the next evolution of Level I Pathways, and will combine input from The US Oncology Network and NCCN.

Q. How are Value Pathways developed?
- Value Pathways are developed by a joint Pathways Task Force consisting of practicing physicians from community and academic practices affiliated with The US Oncology Network, as well as physicians from NCCN Member Institutions.
- Published and presented evidence will be continuously monitored and the Pathways Task Force will vote on proposed changes.
- Users of Value Pathways powered by NCCN are invited to contribute feedback on proposed changes.

Q: How is “cost” defined as it relates to Value Pathways?
- In the absence of publicly available, industry standard comparative data including total cost of care, Value Pathways utilize standard, publicly available cost-based metrics (including Average Sales Price and standard patient responsibility) for required care agents associated with a regimen.

Q. How often are Value Pathways updated?
- The Value Pathway for each disease is reviewed and updated as new, relevant information is available. Additionally, all pathways are reviewed and updated at least once per year.
Q: Is there a process in place for manufacturers to submit meaningful data related to existing or newly launched products as they relate to Value Pathways?
   • Yes. The Pathways Task Force will consider data that may be useful in evaluating the pharmacoeconomic impact of the treatment option for inclusion in a Value Pathway. Guidelines for submission materials are available on our website here.

Q: Is the content of Value Pathways available to manufacturers?
   • At this time, the Value Pathways powered by NCCN are available for practicing physicians using iKnowMed or Clear Value Plus only. If you are considering submitting pharmacoeconomic data and would like to know if your drug is included on Value Pathways, an email can be sent msh.pathways@mckesson.com. Inquires should be specific in nature including drug and disease. Information that will be released will include drug or regimen, disease in question and line of therapy (i.e. Neoadjuvant, Adjuvant, Metastatic 2nd line, etc).

Clear Value Plus

Q: What is Clear Value Plus?
   • Clear Value Plus is the software that allows physicians to assess treatment options of both Value Pathways and NCCN Guidelines at the point of care.

Q: Which EHRs currently integrate with Clear Value Plus?
   • McKesson Specialty Health has agreements to integrate with Varian’s ARIA system, Elekta’s MOSAIQ, in addition to integration with its own iKnowMed EHR platform (both generation one and iKnowMed Generation 2). Other system interfaces may also be supported and are under consideration.

Q: Is Clear Value Plus available to practices outside of The US Oncology Network?
   • Yes. Clear Value Plus is available to all physicians across the country without prerequisites and can act as a stand-alone solution or interface with existing EHRs or EMRs. Any provider seeking to gain greater clinical and financial visibility, or to demonstrate clinical quality through the adherence to evidence-based clinical content such as NCCN Guidelines and Value Pathways, should consider using Clear Value Plus.